GlassScriptPhysician profile
Nicholas M Donin
NPI 1780902015
$25,843.53
in general payments reported to CMS, 2019-2025
18 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.13 · 2021: $69.10 · 2022: $603 · 2023: $768 · 2024: $351 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Travel and Lodging: $3,917 · Food and Beverage: $1,587 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Travel and Lodging | $3,917.00 |
| Food and Beverage | $1,586.78 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $15,600.00 | 2025 | |
| Civco Medical Instruments | $7,937.49 | 2024-2025 | |
| Angiodynamics, INC. | $361.19 | 2023 | Nanoknife |
| Procept Biorobotics Corporation | $357.31 | 2022-2023 | Aquabeam Robotic System |
| Urogen Pharma, INC. | $347.26 | 2022-2024 | Jelmyto |
| Boston Scientific Corporation | $247.12 | 2021-2024 | Lithovue |
| Astrazeneca Pharmaceuticals LP | $169.84 | 2025 | Lynparza, Imfinzi |
| Astellas Pharma US INC | $166.21 | 2022-2025 | Padcev |
| Intuitive Surgical, INC. | $142.57 | 2022-2025 | |
| Olympus America INC. | $129.41 | 2023 | Itind System |
| Janssen Biotech, INC. | $118.08 | 2025 | Rybrevant, Carvykti |
| Sumitomo Pharma America, INC. | $91.74 | 2024-2025 | Gemtesa |
| Abbvie INC. | $58.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $42.46 | 2023-2024 | Bridion |
| Coloplast Corp | $27.01 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $19.69 | 2019 | |
| Profound Medical Corp. | $15.19 | 2022 | |
| Zyla Life Sciences, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Donin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.